Dr. Stephen A. Williams
Dr. Stephen A. Williams is a Board Certified medical oncologist and hematologist. He earned his medical doctorate at the University of Texas Health Science Center in San Antonio, TX. He completed internship and residency at Johns Hopkins University/Sinai Hospital of Baltimore, MD, and subspecialty fellowships in Medical Oncology and Hematology at Georgetown University Hospital/Washington Hospital Center in Washington, DC, including training at the Washington Cancer Institute, the Georgetown Lombardi Cancer Center, and the National Heart, Lung, and Blood Institute at the National Institute of Health in Bethesda, MD.
Dr. Williams came to Roseburg in 2007 to provide patients with personalized, comprehensive care for cancer and blood disorders in a compassionate setting. In addition to his clinical practice, Dr. Williams is president of the Steelhead Specialty group and has served on several local health care boards, including those of DCIPA and Umpqua Health.
Dr. Joshua M. Weese
Dr. Joshua M. Weese is a Board Certified medical oncologist who is also trained in hematology. He has a Bachelor of Science in Physics and Mathematics from Southern Nazarene University. He completed a Master of Business Administration at LeTourneau University. Prior to medical school, he worked in the Allergy/Immunology department at Oklahoma Medical Research Foundation, engaged in research to better understand the underlying genetic and molecular abnormalities of autoimmune disease. Dr. Weese graduated with his medical degree from the University of Oklahoma in 2007, followed by Internal Medicine residency, also at the University of Oklahoma. Dr. Weese completed his Medical Oncology fellowship training at the state of the art Stephenson Cancer Center at the University of Oklahoma. While in training, he participated in clinical trial research from phase 0 thru phase III drug development. Dr. Weese also authored a study evaluating the impact of type 2 diabetes on the development of kidney failure in patients treated with cisplatin, a commonly used chemotherapeutic. Dr. Weese serves as the Chairman of the Joint Cancer Committee. He is also the Executive Vice President and Treasurer of Steelhead Specialty Group.